DKK1, SFRP1, WIF-1, and Wnt5a encode Wnt pathway genes that are frequently silenced by promoter hypermethylation in colorectal cancer. Despite attractive biological consequences of these events, it is unclear whether they contribute to patient prognostication or may influence tumour cell biology within distinct patient subsets. I sought to determine the prognostic roles of these methylation events in a large cohort of colorectal carcinomas from Ontario and Newfoundland. Methylation was quantified and associated with patient clinicopathlogical features. Methylation was present in cancer tissue. DKK1, Wnt5a, and SFRP1 were strongly and independently associated with tumour subtype in a manner that suggested subtype-specific activity of Wnt signaling. Methylation of DKK1 was a borderline prognosticator of favourable outcome. These results offer intriguing insight into subtype-specific biology and lead to a proposed model whereby methylation-induced Wnt bias may contribute to patient outcome.

Introduction: Soft Tissue Injuries (STIs) of the shoulder are common presentations to the Emergency Department but very little is known about the natural history, long-term disability or prognostic factors associated with these injuries. The goals of this pilot study are to describe the three-month outcome of these injuries, to begin to identify prognostic factors associated with poor outcome and to determine the feasibility of a future study aimed at predicting poor outcome. Methods: A cohort of 117 working-age adults presenting to the Emergency Department with acute STIs of the shoulder were prospectively recruited. Patients were interviewed by phone at one week, one month and three months. During the calls, patients completed the Disabilities of the Arm and Shoulder (DASH) questionnaire and provided information about treatments and follow-up that had occurred. Results: Of the 117 subjects, 72.3% had pain and disability above the population norm at one month and that number only decreased to 38.7% at three months. A substantial effect was also seen on Work and Leisure activities. The following prognostic factors were identified as having some association with poor three-month outcome: age, mechanism of injury, ability to rotate arm and abduct arm in ED, pain at one week, whether the injury was work-related, visit with family physician in first week and DASH score (disability) at one week. Conclusions: At the present time, the emergency physician must treat patients with STIs of the shoulder without any substantial knowledge of the morbidity that these injuries cause, which patients are at high risk of poor outcome or what would constitute optimum management. This study has determined that poor outcome is common and it has begun to identify factors that can help predict which patients will have a more complicated course. As it is now felt that the transition from acute to chronic pain begins well before three months, it will be important for future studies to develop a method of early identification of patients at high risk of poor outcome and to determine effective management in an attempt to prevent that transition. / Thesis (Master, Community Health & Epidemiology) -- Queen's University, 2009-08-31 12:12:22.113

Psoriatic Arthritis (PsA) is an inflammatory arthritis associated with psoriasis that leads to progressive joint damage. Genetic variants in the Major Histocompatibility Complex (MHC) region on human chromosome 6p, especially Human Leucocyte Antigen (HLA), are the most important genetic risk variants associated with susceptibility to PsA. I aimed to investigate the heritability of PsA and to determine the association between HLA polymorphisms with susceptibility and severity of PsA. I first validated the new CASPAR classification criteria for PsA in patients in with both early and established disease. Subsequently, I demonstrated that PsA as defined by the CASPAR criteria has a high recurrence risk ratio. In a large case-control and family-based association study, I demonstrated that the class I HLA alleles, HLA-C*12/B*38, -B*27 and -C*06/B*57 are associated with increased susceptibility to PsA. HLA class I molecules biologically interact with Killer-cell Immunoglobulin-like Receptors (KIR) on Natural Killer (NK) to influence immune response. I demonstrated that KIR2DS2 and HLA C group 2 and HLA-B Bw4 were associated with PsA susceptibility. Further analyses of PsA cases with Type II psoriasis and with dactylitis suggested that HLA-C*02, -B*27, -B*38 and KIR2DS2 may be markers of musculoskeletal manifestations of PsA. Furthermore, using longitudinal data, I demonstrated that HLA-B*39, -B*27, -A*02 and KIR3DS1 are associated with peripheral joint damage progression whereas the alleles –DQB1*0604, -C*04 and –B*60 are associated with less damage progression. HLA-C*02, -C*12, -DQB1*0609 and KIR2DS1 are associated with higher risk of sacroiliitis, and HLA-B*27 with syndesmophytes. HLA-A*29 was associated with reduced risk of development of both sacroiliitis and syndesmophytes. These studies indicate that HLA alleles and KIR genes are important in PsA susceptibility and severity and suggest that CD8+ T cells and NK cells that modulate the innate and adaptive immune response play an important role in the susceptibility and severity of PsA.

DKK1, SFRP1, WIF-1, and Wnt5a encode Wnt pathway genes that are frequently silenced by promoter hypermethylation in colorectal cancer. Despite attractive biological consequences of these events, it is unclear whether they contribute to patient prognostication or may influence tumour cell biology within distinct patient subsets. I sought to determine the prognostic roles of these methylation events in a large cohort of colorectal carcinomas from Ontario and Newfoundland. Methylation was quantified and associated with patient clinicopathlogical features. Methylation was present in cancer tissue. DKK1, Wnt5a, and SFRP1 were strongly and independently associated with tumour subtype in a manner that suggested subtype-specific activity of Wnt signaling. Methylation of DKK1 was a borderline prognosticator of favourable outcome. These results offer intriguing insight into subtype-specific biology and lead to a proposed model whereby methylation-induced Wnt bias may contribute to patient outcome.

Psoriatic Arthritis (PsA) is an inflammatory arthritis associated with psoriasis that leads to progressive joint damage. Genetic variants in the Major Histocompatibility Complex (MHC) region on human chromosome 6p, especially Human Leucocyte Antigen (HLA), are the most important genetic risk variants associated with susceptibility to PsA. I aimed to investigate the heritability of PsA and to determine the association between HLA polymorphisms with susceptibility and severity of PsA. I first validated the new CASPAR classification criteria for PsA in patients in with both early and established disease. Subsequently, I demonstrated that PsA as defined by the CASPAR criteria has a high recurrence risk ratio. In a large case-control and family-based association study, I demonstrated that the class I HLA alleles, HLA-C*12/B*38, -B*27 and -C*06/B*57 are associated with increased susceptibility to PsA. HLA class I molecules biologically interact with Killer-cell Immunoglobulin-like Receptors (KIR) on Natural Killer (NK) to influence immune response. I demonstrated that KIR2DS2 and HLA C group 2 and HLA-B Bw4 were associated with PsA susceptibility. Further analyses of PsA cases with Type II psoriasis and with dactylitis suggested that HLA-C*02, -B*27, -B*38 and KIR2DS2 may be markers of musculoskeletal manifestations of PsA. Furthermore, using longitudinal data, I demonstrated that HLA-B*39, -B*27, -A*02 and KIR3DS1 are associated with peripheral joint damage progression whereas the alleles –DQB1*0604, -C*04 and –B*60 are associated with less damage progression. HLA-C*02, -C*12, -DQB1*0609 and KIR2DS1 are associated with higher risk of sacroiliitis, and HLA-B*27 with syndesmophytes. HLA-A*29 was associated with reduced risk of development of both sacroiliitis and syndesmophytes. These studies indicate that HLA alleles and KIR genes are important in PsA susceptibility and severity and suggest that CD8+ T cells and NK cells that modulate the innate and adaptive immune response play an important role in the susceptibility and severity of PsA.

No description available.

Background: It is well recognized that not all patients with stage C colorectal cancer (CRC) derive a survival benefit from adjuvant chemotherapy. It would therefore be advantageous to identify factors that define a target group for treatment. It has been suggested that those most likely to benefit are women with proximal tumours. Recent work has suggested microsatellite instability (MSI) may be a useful marker however the limited studies performed are conflicting. Aim: To determine if gender, site, tumour histology or microsatellite (MSI) status predict survival benefit from 5FU-based adjuvant chemotherapy in stage C CRC. Method: Data was collated on stage C colorectal cancer cases that underwent curative resection over a 20-year period (inclusive of years prior to standard chemotherapy). Pathology was re-evaluated, DNA extracted from the formalin fixed paraffin specimen and MSI status established. Primary endpoint was cancer-related death. Kaplan-Meier curves were constructed for univariate analysis and differences analysed by log rank test. Multivariate analysis was performed using Cox proportional hazard model adjusting for age, gender, site, distinct pathological variables and MSI. A compounding effect between these factors and chemotherapy benefit was measured by interaction testing Results: 811 unselected cases were included in the study. Thirty-seven percent received chemotherapy. Chemotherapy significant improved cancer-specific survival (HR of dying 0.66 (95% CI 0.52-0.83 p=0.0003). Female gender offered a survival advantage overall (HR 0.81 95% CI 0.68-0.97; p=0.02) however site did not influence outcome (HR 1.03). On interaction testing, gender, site and tumour histology did not significantly influence the survival effect of chemotherapy. 802 cases were included in the MSI analysis of which 77 exhibited MSI. MSI status did not influence prognosis (HR of cancer death 1.45, 95% CI 0.90-2.21; p= 0.13). However, in the non-chemotherapy cohort, MSI conferred a significantly less favourable outcome (HR 1.89, 95%CI 1.13-3.16; p= 0.02). Chemotherapy produced a survival benefit in both the MSI (HR 0.08 95% CI 0.02-0.27; p=<0.0001) and the microsatellite stable (MSS) cohort (HR 0.62, 95% CI 0.47-0.81; p=0.001). On interaction testing, neither compounded the benefit of chemotherapy, however of all the tested parameters, MSI came closest to significance (p=0.08). Conclusion: These results suggest that 5FU-based adjuvant chemotherapy for stage C colorectal cannot be targeted using gender, tumour site, histological characteristics or MSI. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1522132 / Thesis (Ph.D.) -- University of Adelaide, School of Medicine, 2010

Thesis (doctoral)--Lund University, 1998. / Added t.p. with thesis statement inserted.

Thesis (doctoral)--Lund University, 1998. / Added t.p. with thesis statement inserted.

Thesis (doctoral)--Universiteit van Amsterdam.